Genmab A/S (NASDAQ:GMAB) Receives Average Recommendation of “Hold” from Analysts

Genmab A/S (NASDAQ:GMAB) has been given a consensus rating of “Hold” by the thirteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $48.50.

GMAB has been the subject of several research analyst reports. Morgan Stanley reaffirmed an “underweight” rating on shares of Genmab A/S in a report on Tuesday, March 26th. BMO Capital Markets raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $46.00 to $48.00 in a report on Friday, February 23rd. Citigroup downgraded shares of Genmab A/S from a “neutral” rating to a “sell” rating in a report on Monday, January 22nd. HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a report on Thursday, April 4th. Finally, Truist Financial reissued a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Tuesday, March 26th.

Institutional Trading of Genmab A/S

A number of institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its holdings in shares of Genmab A/S by 42.7% during the 1st quarter. JPMorgan Chase & Co. now owns 135,116 shares of the company’s stock worth $4,889,000 after acquiring an additional 40,444 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Genmab A/S by 4.2% during the 1st quarter. Bank of New York Mellon Corp now owns 116,847 shares of the company’s stock worth $4,227,000 after acquiring an additional 4,665 shares during the period. Private Advisor Group LLC lifted its holdings in shares of Genmab A/S by 24.0% during the 1st quarter. Private Advisor Group LLC now owns 20,119 shares of the company’s stock worth $728,000 after acquiring an additional 3,891 shares during the period. BlackRock Inc. lifted its holdings in shares of Genmab A/S by 1.6% during the 1st quarter. BlackRock Inc. now owns 5,494,689 shares of the company’s stock worth $198,799,000 after acquiring an additional 86,571 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Genmab A/S by 18.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 18,243 shares of the company’s stock worth $660,000 after acquiring an additional 2,792 shares during the period. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Price Performance

Genmab A/S stock opened at $28.33 on Friday. The firm has a market capitalization of $18.73 billion, a PE ratio of 29.51, a P/E/G ratio of 2.11 and a beta of 0.99. The company’s 50-day moving average is $29.36 and its 200-day moving average is $30.34. Genmab A/S has a fifty-two week low of $26.32 and a fifty-two week high of $42.72.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, February 14th. The company reported $0.36 EPS for the quarter, topping the consensus estimate of $0.34 by $0.02. The business had revenue of $675.29 million during the quarter, compared to the consensus estimate of $678.14 million. Genmab A/S had a net margin of 26.50% and a return on equity of 18.06%. As a group, analysts expect that Genmab A/S will post 1.06 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.